Boule Diagnostics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
July 24, 2023 at 01:30 am EDT
Share
Boule Diagnostics AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 140.5 million compared to SEK 140.8 million a year ago. Net income was SEK 4.1 million compared to SEK 2.9 million a year ago. Basic earnings per share from continuing operations was SEK 0.11 compared to SEK 0.11 a year ago. Diluted earnings per share from continuing operations was SEK 0.11 compared to SEK 0.1 a year ago.
For the six months, sales was SEK 283.6 million compared to SEK 273.3 million a year ago. Net income was SEK 12 million compared to SEK 7.5 million a year ago. Basic earnings per share from continuing operations was SEK 0.31 compared to SEK 0.27 a year ago.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
